Amarantus gets orphan drug approval for MANF
The FDA has granted Amarantus BioScience Holdings’ (OTCQB:AMBS) investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) orphan drug designation for the treatment of retinitis...
View ArticleAmarantus forms Alzheimer’s disease SAB
Amarantus BioScience Holdings (OTCQB:AMBS) has established an Alzheimer’s disease (AD) diagnostics scientific advisory board (SAB) and appointed three internationally-renowned specialists in AD and...
View ArticleAmarantus eltoprazine PD data published
Amarantus BioSciences Holdings (OTCQB:AMBS) announced the publication of results of a Phase 2a study of eltoprazine in Parkinson’s disease levodopa-induced dyskinesias (PD-LID). The paper titled,...
View ArticleAmarantus to present LymPro poster at AD/PD 2015
Amarantus BioSciences Holdings’ (OTCQB:AMBS) abstract titled, “The LymPro Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively...
View ArticleAmarantus to start Phase 2b with eltoprazine in PD
Amarantus BioScience Holdings (OTCQB:AMBS) has an active IND application with the neurology division of the FDA to start a Phase 2b program of eltoprazine for the treatment of Parkinson’s disease...
View ArticleAmarantus posts blood-based data from MSPrecise
Amarantus BioScience Holdings (OTCQB:AMBS) has reported preliminary data from the blood-based version of its MSPrecise diagnostic test for multiple sclerosis. MSPrecise, a next-generation DNA...
View ArticleAmarantus posts positive PD preclinical data with MANF
Amarantus BioScience Holdings (OTCQB:AMBS) has completed a study of MANF (mesencephalic-astrocyte-derived neurotrophic factor) administration to the putamen and the substantia nigra of pigs by...
View ArticleAmarantus in capital restructuring to up-list shares
Amarantus BioSciences Holdings (OTCQB:AMBS) has implemented a 1-for-150 reverse stock split of its common stock to facilitate listing its shares on a national exchange this year. Trading on a...
View ArticleAmarantus begins enrollment in PD study of eltoprazine
Amarantus BioScience Holdings (OTCQB:AMBS) has opened the first clinical trial site for enrollment for a Phase 2b study of its lead product candidate, eltoprazine, for the treatment of Parkinson’s...
View ArticleAmarantus begins trading on OTCQX
Amarantus BioScience Holdings (OTCQX:AMBS) received approval to begin trading on the OTCQX Best Marketplace at the open today, under its existing ticker symbol, AMBS. In a statement, Gerald...
View Article
More Pages to Explore .....